Clinical Laserthermia Systems AB Class B

Clinical Laserthermia Systems AB TEMP Class B's next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, Clinical Laserthermia Systems AB TEMP Class B has 7.07M shares outstanding.

As of June 30, 2026, Clinical Laserthermia Systems AB TEMP Class B maintains a current ratio of 0.94, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Clinical Laserthermia Systems AB TEMP Class B posted a negative return on equity (ROE) of -68.65, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -56.97, reflecting losses generated across the asset base. The company generates approximately 965,846.15 in revenue per employee across its workforce of 13.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.87 indicates how many times Clinical Laserthermia Systems AB TEMP Class B sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on September 3, 2026, Clinical Laserthermia Systems AB TEMP Class B's stock has gained approximately 30.41% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Clinical Laserthermia Systems AB TEMP Class B generated 12.56M in revenue and converted that into -39.49M in net income, yielding earnings per share of -5.92. EBITDA reached -38.56M, while operating income came in at -41.21M.

These figures are as of June 30, 2026. Total book value stands at 47.84M, with working capital of -1.59M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Clinical Laserthermia Systems AB TEMP Class B posted a gross margin of 55.56, reflecting its pricing power and cost economics. The operating margin of -328.20 and net profit margin of -314.55 provide insight into operational efficiency.